SAN

76.92

-0.75%↓

UCB

247.8

+0.85%↑

SHL.DE

36.68

+0.38%↑

ARGX

587.6

+0.24%↑

VIE

31.56

+1.54%↑

SAN

76.92

-0.75%↓

UCB

247.8

+0.85%↑

SHL.DE

36.68

+0.38%↑

ARGX

587.6

+0.24%↑

VIE

31.56

+1.54%↑

SAN

76.92

-0.75%↓

UCB

247.8

+0.85%↑

SHL.DE

36.68

+0.38%↑

ARGX

587.6

+0.24%↑

VIE

31.56

+1.54%↑

SAN

76.92

-0.75%↓

UCB

247.8

+0.85%↑

SHL.DE

36.68

+0.38%↑

ARGX

587.6

+0.24%↑

VIE

31.56

+1.54%↑

SAN

76.92

-0.75%↓

UCB

247.8

+0.85%↑

SHL.DE

36.68

+0.38%↑

ARGX

587.6

+0.24%↑

VIE

31.56

+1.54%↑

Search

ICADE.

Closed

SectorHealthcare

19.39 -0.67

Overview

Share price change

24h

Current

Min

18.7

Max

19.72

Key metrics

By Trading Economics

Income

60M

-31M

Sales

84M

707M

EPS

-0.41

Profit margin

-4.427

Employees

983

EBITDA

-152M

-14M

Recommendations

By TipRanks

Recommendations

Strong Sell

12 Months Forecast

+1.85% upside

Market Stats

By TradingEconomics

Market Cap

-53M

1.5B

Previous open

20.06

Previous close

19.39

News Sentiment

By Acuity

50%

50%

147 / 350 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

ICADE. Chart

Past performance is not a reliable indicator of future results.

Related News

23 Mar 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 Mar 2026, 22:55 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 Mar 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 Mar 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 Mar 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 Mar 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 Mar 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 Mar 2026, 22:42 UTC

Market Talk
Major News Events

Global Equities Roundup: Market Talk

23 Mar 2026, 22:42 UTC

Market Talk
Major News Events

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 Mar 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 Mar 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 Mar 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 Mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 Mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 Mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 Mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 Mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 Mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 Mar 2026, 22:18 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 Mar 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 Mar 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 Mar 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 Mar 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 Mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 Mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 Mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 Mar 2026, 21:10 UTC

Major News Events

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 Mar 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 Mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 Mar 2026, 20:50 UTC

Market Talk
Earnings
Major News Events

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

ICADE. Forecast

Price Target

By TipRanks

1.85% upside

12 Months Forecast

Average 19.82 EUR  1.85%

High 25 EUR

Low 17.1 EUR

Based on 5 Wall Street analysts offering 12 month price targets forICADE. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Sell

5 ratings

0

Buy

1

Hold

4

Sell

Technical Score

By Trading Central

21.04 / 21.4Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

147 / 350 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About ICADE.

Icade is a full-service real estate company with expertise in both commercial property investment (portfolio worth "6.8bn on a full consolidation basis as of 12/31/2023) and property development (2023 economic revenue of "1.3bn) that operates throughout France. Icade has forged longterm partnerships to respond to emerging trends in the industry. It has made climate issues and the preservation of biodiversity central to its business model to reinvent real estate and contribute to more sustainable cities. It is listed as a "SIIC" on Euronext Paris and its leading shareholder is the Caisse des Dépôts group.
help-icon Live chat